pain

Red stop sign on road

Biotech

Eli Lilly sidelines pain prospect in another pipeline shift

The asset was originally licensed from Asahi Kasei Pharma in 2021, and Lilly is now exploring other possible indications for the P2X7 inhibitor.

Darren Incorvaia Oct 30, 2025 2:19pm

dart board miss failure

Vertex drops asset in acute pain after phase 2 fail

Aug 4, 2025 5:34pm

AstraZeneca culls neuroscience meds in Q1 clear-out

Apr 29, 2025 7:08am

X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm

power lines at dusk

Novo Holdings-backed SiteOne charges up with $100M financing

Dec 18, 2024 7:00am

stop shut down close end button

Lundbeck slashes value of $250M Abide buyout after pain setback

Oct 24, 2024 7:20am